Engimmune Therapeutics
PrivateLast Round
Seed
May 3, 2022
Total Funding Raised
$16.7M
Company Overview
Engimmune Therapeutics is a biotechnology company that develops targeted, 'off-the-shelf' soluble T-cell receptor (TCR) drugs to treat solid tumour cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Engimmune Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Engimmune Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | May 3, 2022 |
Engimmune Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Novo Holdings | Seed |
| Pureos Bioventures | Seed |
| BaseLaunch | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 16, 2023
Grew 19% QoQ, from 21 to 25 employees.
- May 3, 2022
$17M round led by Novo Holdings and Pureos Bioventures.
Engimmune Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Engimmune Therapeutics's valuation, stock price, and market status.
